Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2018

01-06-2018 | Introduction to Review Articles

Time has come for proton and carbon beam therapy

Author: Hiroki Shirato

Published in: International Journal of Clinical Oncology | Issue 3/2018

Login to get access

Excerpt

Yoichiro Umegaki, a pioneer of radiation oncology in Japan, proposed to start proton therapy with a cyclotron at the National Institute of Radiological Sciences (NIRS) in 1971 for eye tumors and with a synchrotron at the Research Institute of High Energy Physics, Tsukuba (KEK) in 1973 for deep-seated tumors [1]. In 1978, he reported to the Government of Japan that “proton beam is the best for practical radiotherapy. Heavy ions should be studied for the purpose of further future development of particle radiotherapy” Hiroshi Tsunemoto, a successor to Umegaki, concluded that “In the future, we must go to protons and heavy ions” in 1982 [2]. …
Literature
1.
go back to reference Umegaki Y (1994) Medical use of particle accelerators. In Basic and clinical studies on the radiotherapy of cancer. Nakayama Institute of Cancer Research. ISBN: 4-906225-22-5 C3047 Umegaki Y (1994) Medical use of particle accelerators. In Basic and clinical studies on the radiotherapy of cancer. Nakayama Institute of Cancer Research. ISBN: 4-906225-22-5 C3047
2.
go back to reference Tsunemoto H (1982) Clinical evaluation of fast neutron therapy. Nihon Igaku Hoshasen Gakkai Zasshi 42(9):823–847 (Japanese. PubMed PMID: 6819541) PubMed Tsunemoto H (1982) Clinical evaluation of fast neutron therapy. Nihon Igaku Hoshasen Gakkai Zasshi 42(9):823–847 (Japanese. PubMed PMID: 6819541) PubMed
3.
go back to reference Tanaka N, Matsuzaki Y, Chuganji Y et al (1992) Proton irradiation for hepatocellular carcinoma. Lancet 340(8831):1358 PubMed PMID: 1360077 CrossRefPubMed Tanaka N, Matsuzaki Y, Chuganji Y et al (1992) Proton irradiation for hepatocellular carcinoma. Lancet 340(8831):1358 PubMed PMID: 1360077 CrossRefPubMed
Metadata
Title
Time has come for proton and carbon beam therapy
Author
Hiroki Shirato
Publication date
01-06-2018
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-018-1263-x

Other articles of this Issue 3/2018

International Journal of Clinical Oncology 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine